In short
Clinical trials investigating Indometacin are studies focused on what is being tested, in whom, and for what purpose. The trial data provided here describes research in patients with retinitis pigmentosa and gene-related eye disease, with a focus on safety and efficacy outcomes.
Key points
- Only one trial is provided in the source data, and it is a Phase 1/2 study in patients with retinitis pigmentosa linked to PDE6B gene mutations. The study is completed and included 23 participants. Its main goal was to assess safety after unilateral subretinal administration of the study treatment. The main outcomes focused on eye exams, inflammation, tissue tolerance, questionnaires, vital signs, and laboratory tests. The source data does not provide a broader set of Indometacin trials, so the article reflects only this specific study record.
Trial overview
The provided trial record is a Phase 1/2 interventional study that was completed and enrolled 23 participants. It studied patients with retinitis pigmentosa linked to mutations in the PDE6B gene and a defect in PDE6ß expression. The brief aim was to assess the safety of a unilateral subretinal administration of HORA-PDE6B.
Who was studied
The target population was very specific: patients with retinitis pigmentosa who carried PDE6B gene mutations. This means the trial was not for all people with eye disease, but for a smaller group with a known genetic cause. In simple words, the study focused on people whose vision problem was linked to a particular inherited gene change.
The trial was also limited to treatment in one eye only, which is what unilateral means. This kind of design can help researchers compare safety in the treated eye with the untreated eye when needed.
What was tested
The main study treatment described in the record was a subretinal administration of HORA-PDE6B, which means the treatment was placed under the retina. The trial title also lists several eye medicines and supportive treatments, including atropine, CHIBRO CADRON, INDOCOLLYRE 0,1 %, MYDRIASERT, and dexamethasone, as part of the study procedures. The source data does not say these were the main research question; the main goal remained safety of the subretinal study treatment.
Trial phase and design
This was an interventional trial, which means the research team gave a treatment and then observed the results. The study phase was Phase 1/2, an early stage that usually looks first at safety and then at early signs that a treatment may help. Because it was completed, the study has already finished collecting its planned data.
Outcomes and endpoints
The primary outcome was safety, measured through routine ophthalmic examination, intraocular inflammation, chorioretinal tolerance, questionnaire results, vital signs, and laboratory measurements. These are standard ways to check whether the eye and the rest of the body handled the treatment well. In patient terms, the study looked for signs of eye irritation, changes in the back of the eye, and any general health changes during the trial.
The record also mentions safety and efficacy in the title, but the only endpoint described in the source data is the safety-focused primary endpoint. Because of that, the clearest trial message is that this study was mainly designed to see if the treatment could be given safely in this patient group.
Patient-focused terms
Ophthalmic examination means a standard eye check-up used to look at the eye and vision-related structures. Inflammation means swelling or irritation, and in this study it was checked inside the eye. Laboratory measurements are blood or other test results that help show whether the body is responding safely to treatment.
Chorioretinal tolerance refers to how well the back layers of the eye, including the choroid and retina, can handle the treatment. Questionnaires are forms completed by patients to report symptoms or how they feel during the study. Together, these measures help researchers build a full picture of safety in a small early-stage trial.